Clinical application of stem cell therapy in neurogenic bladder: a systematic review and meta-analysis
Hanieh Salehi-pourmehr,Ozra Nouri,Amirreza Naseri,Leila Roshangar,Reza Rahbarghazi,Saeed Sadigh-Eteghad,Javad Mahmoudi,Hadi Mostafaei,M. Reza Roshandel,Leila Hoseini,Nasrin Abolhasanpour,Ali Mostafaei,Sakineh Hajebrahimi,Hashim Hashim
DOI: https://doi.org/10.1007/s00192-021-04986-6
2021-11-12
International Urogynecology Journal
Abstract:Introduction and hypothesisThis review aims to investigate the effect of stem cell (SC) therapy on the management of neurogenic bladder (NGB) in four neurological diseases, including spinal cord injury (SCI), Parkinson’s disease (PD), multiple sclerosis (MS), and stroke, in the clinical setting.MethodsAn electronic database search was conducted in the Cochrane Library, EMBASE, Proquest, Clinicaltrial.gov, WHO, Google Scholar, MEDLINE via PubMed, Ovid, Web of Science, Scopus, ongoing trial registers, and conference proceedings in June 2019 and updated by hand searching on 1 February 2021. All randomized controlled trials (RCTs), quasi RCTs, phase I/II clinical trials, case-control, retrospective cohorts, and comprehensive case series that evaluated the regenerative potential of SCs on the management of NGB were included. Cochrane appraisal risk of bias checklist and the standardized critical appraisal instrument from the JBI Meta-Analysis of Statistics, Assessment, and Review Instrument (JBI-MAStARI) were used to appraise the studies.ResultsTwenty-six studies among 1282 relevant publications met our inclusion criteria. Only SC therapy was applied for SCI or MS patients. Phase I/II clinical trials (without control arm) were the most conducted studies, and only four were RCTs. Four studies with 153 participants were included in the meta-analysis. The main route of transplantation was via lumbar puncture. There were no serious adverse events. Only nine studies in SCI and one in MS have used urodynamics, and the others have reported improvement based on patient satisfaction. SC therapy did not significantly improve residual urine volume, detrusor pressure, and maximum bladder capacity. Also, the quality of these publications was low or unclear.ConclusionAlthough most clinical trials provide evidence of the safety and effectiveness of MSCs on the management of NGB, the meta-analysis results did not show a significant improvement; however, the interpretation of study results is difficult because of the lack of placebo controls.
urology & nephrology,obstetrics & gynecology